{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:31:46Z","timestamp":1787311906480,"version":"build-2736575974"},"reference-count":16,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2011,10,10]]},"published-print":{"date-parts":[[2012]]},"abstract":"<jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective audit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Secondary paediatric outpatient clinic, Troms\u00f8, Norway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The participants were 80 (62.5% boys and 37.5% girls) children and adolescents with a diagnosed egg allergy who had to be on an egg-free diet and be unable to eat any food containing any amount of egg, including egg-containing baked goods, without an allergic reaction to egg protein. We also included patients who were sensitised to egg but had never been exposed to egg or egg-containing baked goods and were on an egg-free diet. Other atopic diseases among the study participants were also registered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>The vaccination took place from November to December 2009. The patients were vaccinated with a monovalent influenza A (H1N1) vaccine that had an ovalbumin content &lt;0.33\u2005\u03bcg\/ml. They were divided into two groups, receiving the vaccine either as a single dose or as a fractionated dose. Patients were selected for the fractionated dose because of their prior reaction to egg or because they never had been exposed to egg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome<\/jats:title>\n                    <jats:p>There were no serious adverse reactions to the vaccine; only one mild adverse reaction and two possible adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients ranged in age from 10\u2005months to 16.5\u2005years. Thirty-eight (48%) patients received a fractionated dose. Sixty-three (79%) had one or more atopic disease apart from egg allergy. With regard to atopy, serum specific IgE levels or skin prick test, there were no significant differences between the groups receiving the vaccine as a fractionated or as a single dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study confirmed that patients allergic to egg can be safely vaccinated with a regular influenza vaccine containing &lt;0.333\u2005\u03bcg\/ml ovalbumin, even if these patients had displayed previous anaphylactic reactions to egg and had been diagnosed with concurrent atopic diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2011-000186","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T06:10:06Z","timestamp":1325830206000},"page":"e000186","source":"Crossref","is-referenced-by-count":12,"title":["Reactions of Norwegian children with severe egg allergy to an egg-containing influenza A (H1N1) vaccine: a retrospective audit: Table 1"],"prefix":"10.1136","volume":"2","author":[{"given":"B\u00e5rd Anders","family":"Forsdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,1,5]]},"reference":[{"key":"2025121601014294000_2.1.e000186.1","first-page":"301","article-title":"Human infection with pandemic A (H1N1) 2009 influenza virus: clinical observations in hospitalized patients, Americas","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"2025121601014294000_2.1.e000186.2","unstructured":"Norwegian Health Authorities. \u00d8kt influensaaktivitet og ny vaksineanbefaling. 2009. http:\/\/www.fhi.no\/eway\/default.aspx?pid=233&trg=MainLeft_6129&MainArea_5661=6129:0:15,5004:1:0:0:::0:0&MainLeft_6129=5544:80624::1:6130:13:::0:0"},{"key":"2025121601014294000_2.1.e000186.3","unstructured":"World Health Organisation. Use of the Pandemic (H1N1) 2009 Vaccines. http:\/\/www.who.int\/csr\/disease\/swineflu\/frequently_asked_questions\/vaccine_preparedness\/use\/en\/index.html"},{"key":"2025121601014294000_2.1.e000186.4","unstructured":"Centers for Disease Control and Prevention. General Questions and Answers on 2009 H1N1 Influenza Vaccine Safety. http:\/\/www.cdc.gov\/h1n1flu\/vaccination\/vaccine_safety_qa.htm#c"},{"key":"2025121601014294000_2.1.e000186.5","unstructured":"American Academy of Pediatrics. Influenza. In: Pickering LK Baker CJ Kimberlin DW , eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2009:400\u201312."},{"key":"2025121601014294000_2.1.e000186.6","unstructured":"The Norwegian Health Authorities. 4 December 2009. http:\/\/www.fhi.no\/eway\/default.aspx?pid=233&trg=Area_5626&MainArea_5661=5619:0:15,4665:1:0:0:::0:0&MainLeft_5619=5626:81582::1:5625:1:::0:0&Area_5626=5544:81587::1:5628:3:::0:0"},{"key":"2025121601014294000_2.1.e000186.7","unstructured":"The Norwegian Health Authorities. 28 October 2009. http:\/\/www.fhi.no\/eway\/default.aspx?pid=233&trg=MainLeft_5565&MainArea_5661=5565:0:15,5034:1:0:0:::0:0&MainLeft_5565=5544:80779::1:5569:2:::0:0"},{"key":"2025121601014294000_2.1.e000186.8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/bmj.b3680","article-title":"Recommendations for the administration of influenza vaccine in children allergic to egg","volume":"339","author":"Erlewyn-Lajeunesse","year":"2009","journal-title":"BMJ"},{"key":"2025121601014294000_2.1.e000186.9","unstructured":"Norwegian Health Authorities. \u00c9n dose Pandemrix tilstrekkelig for de fleste barn og voksne. 15 December 2009. http:\/\/www.fhi.no\/eway\/default.aspx?pid=233&trg=MainLeft_5565&MainArea_5661=5565:0:15,5034:1:0:0:::0:0&MainLeft_5565=5544:81734::1:5569:2:::0:0"},{"key":"2025121601014294000_2.1.e000186.10","unstructured":"American Academy of Pediatrics. Active immunization. In: Pickering LK Baker CJ Long SS , eds. Red Book: 2006 Report of the Committee of Infectious Diseases. 27th edn. Elk Grove Village, IL: American Academy of pediatrics, 2006:9\u201354."},{"key":"2025121601014294000_2.1.e000186.11","unstructured":"Branum AM Lukacs SL . Food Allergy Among U.S. Children: Trends in Prevalence and Hospitalizations. NCHS data brief, no 10. Hyattsville, MD: National Center for Health Statistics, 2008."},{"key":"2025121601014294000_2.1.e000186.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70101-5"},{"key":"2025121601014294000_2.1.e000186.13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2512"},{"key":"2025121601014294000_2.1.e000186.14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaci.2010.05.037","article-title":"Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine","volume":"126","author":"Gagnon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2025121601014294000_2.1.e000186.15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2010.08.015","article-title":"The safety of the H1N1 influenza A vaccine in egg allergic individuals","volume":"105","author":"Greenhawt","year":"2010","journal-title":"ANN Allergy Asthma Immunol"},{"key":"2025121601014294000_2.1.e000186.16","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.104941"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2011-000186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:01:59Z","timestamp":1765875719000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2011-000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,5]]},"published-print":{"date-parts":[[2012]]}},"alternative-id":["10.1136\/bmjopen-2011-000186"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2011-000186","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}